Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

PIPE-505

Other · developed by Contineum Therapeutics

Phase 1/2 Most advanced trial (none active)
CTNM Developer
1 Registered trials

What is PIPE-505?

PIPE-505 is an investigational drug studied in Sensorineural Hearing Loss.

At a glance

Drug type
Other
Therapy area
Ear, nose & throat
Developer
Contineum Therapeutics (CTNM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04462198 Phase 1/2 Sensorineural Hearing Loss Completed CTNM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Sensorineural Hearing Loss

More from Contineum Therapeutics

PIPE-307 Phase 1 PIPE-791 Phase 2

Follow CTNM, the company behind PIPE-505

See CTNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CTNM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.